Medical Technology

@xconomy.com 4 years ago

With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14

@xconomy.com 4 years ago

Five Years After Y Combinator First Admits Biotechs, They’re Dug In

@xconomy.com 4 years ago

As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing

@xconomy.com 4 years ago

At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments

@xconomy.com 5 years ago

Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More

@xconomy.com 5 years ago

ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On

@xconomy.com 5 years ago

With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?

@xconomy.com 5 years ago

In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine

@xconomy.com 5 years ago

Iora Health Goes Big With $100M to Advance Collaborative Care Model